Theratechnologies Inc. appointed Gary Littlejohn as a new independent director to its board.

Littlejohn most recently worked as interim CEO of Helix BioPharma Corp.

The company's board decided to appoint additional directors, taking into account the growth of the company, said Dawn Svoronos, chair of the Theratechnologies board.

Theratechnologies is a Canadian specialty pharmaceutical company focused on developing therapies for orphan medical conditions, including HIV.